A5069585976- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Neutropenia and Cancer Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- Nail Diseases and Treatments
- Viral-associated cancers and disorders
- Mycobacterium research and diagnosis
- Lymphoma Diagnosis and Treatment
- Infectious Diseases and Mycology
- Chemotherapy-related skin toxicity
- Plant Pathogens and Fungal Diseases
- Bacterial Identification and Susceptibility Testing
- CNS Lymphoma Diagnosis and Treatment
- Antibiotic Resistance in Bacteria
- HIV/AIDS oral health manifestations
- Fungal Biology and Applications
- Cancer and Skin Lesions
- HIV/AIDS drug development and treatment
- Parasitic Diseases Research and Treatment
- Ocular Infections and Treatments
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Antimicrobial Resistance in Staphylococcus
- Infections and bacterial resistance
- Oral health in cancer treatment
Helios Vogtland Klinikum Plauen
2020-2025
Helios Kliniken
2023-2024
Paracelsus-Kliniken
2014-2021
Evangelisches Krankenhaus Bielefeld
2020
Charité - Universitätsmedizin Berlin
2008-2018
Humboldt-Universität zu Berlin
2004-2018
European Society of Clinical Microbiology and Infectious Diseases
2018
Humboldt State University
1996-2011
Radboud University Nijmegen
2006-2008
Radboud University Medical Center
2008
Invasive fungal diseases are important causes of morbidity and mortality. Clarity uniformity in defining these infections factors improving the quality clinical studies. A standard set definitions strengthens consistency reproducibility such studies.After introduction original European Organization for Research Treatment Cancer/Invasive Fungal Infections Cooperative Group National Institute Allergy Infectious Diseases Mycoses Study (EORTC/MSG) Consensus definitions, advances diagnostic...
To evaluate the efficacy and safety of voriconazole in acute invasive aspergillosis (IA), an open, noncomparative multicenter study was conducted. Immunocompromised patients with IA were treated intravenously administered 6 mg/kg twice a day (b.i.d.) then 3 b.i.d. for 6-27 days, followed by 200 mg orally up to 24 weeks. Response assessed clinical radiographic change. A total 116 assessable. proven 48 (41%) probable 68 patients. Voriconazole given as primary therapy 60 (52%). Good responses...
Treatment of invasive mold infection in immunocompromised patients remains challenging. Voriconazole has been shown to have efficacy and survival benefits over amphotericin B deoxycholate, but its utility is limited by drug interactions. Liposomal achieves maximum plasma levels at a dosage 10 mg/kg per day, clinical data for higher doses are lacking.In double-blind trial, with proven or probable were randomized receive liposomal either 3 day 14 days, followed day. The primary end point was...
The Infectious Diseases Working Party (AGIHO) of the German Society Hematology and Oncology (DGHO) here presents its updated recommendations for treatment documented fungal infections. Invasive infections are a main cause morbidity mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, already approved studied indications. choice most appropriate depends on species suspected or identified, patient's risk factors...
Abstract The EORTC/MSGERC recently revised and updated the consensus definitions of invasive fungal disease (IFD). These primarily focus on patients with cancer stem cell or solid-organ transplant patients. They may therefore not be suitable for intensive care unit (ICU) More in detail, while definition proven IFD applies to a broad range hosts, categories probable possible were designed classical immunocompromised hosts ideal other populations. Moreover, scope category has been diminished...
From each of two AIDS patients with oropharyngeal candidiasis, five Candida albicans isolates from recurrent episodes infection which became gradually resistant against fluconazole during antimycotic treatment were analyzed for molecular changes responsible drug resistance. In both patients, a single C. strain was the infections, but CARE-2 fingerprint pattern exhibited minor genetic alterations, indicating that microevolution strains took place therapy. patient 1, enhanced mRNA levels MDR1...
After repeated use of fluconazole for therapy oropharyngeal candidosis, the emergence in vitro fluconazole-resistant Candida albicans isolates (MIC, > or = 25 micrograms/ml) together with oral candidosis unresponsive to dosages up 400 mg were observed patients human immunodeficiency virus (HIV) infection. Antifungal susceptibility testing was done by broth microdilution and agar dilution techniques on C. recovered from a cohort symptomatic HIV infection who treated repeatedly candidosis....
Background. Ocular candidiasis is a major complication of candidemia. The incidence, risk factors, and outcome eye involvement during candidemia are largely unknown. We prospectively studied the ocular manifestations in large, worldwide, randomized multicenter trial that compared voriconazole with amphotericin B followed by fluconazole for treatment
There is no widely accepted standard for antifungal prophylaxis in patients with hematologic malignancies. The Infectious Diseases Working Party of the German Society Haematology and Oncology assigned a committee hematologists infectious disease specialists to develop recommendations. Literature data bases were systematically searched clinical trials on prophylaxis. studies identified shared within committee. Data extracted by two authors (OAC MSi). consensus process was conducted email...
Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk who have received trimethoprim–sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear...